Daniel Savitt, DO
Neurology · Scottsdale, AZNPI 1992149603
Payments from drug & device makers
Across 41 payments — averaging $1519.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$55K
- Medtronic$6K
- Boston Scientific$161
- Argenx US, Inc.$104
- Acorda Therapeutics, Inc$60
- Biogen$53
- plus $93 from 5 others
What the payments were for
- Speaking & faculty fees$601%
- Grants$6,25091%
- Food & beverage$5858%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $55,415 |
| Medtronic(2 entities) | 5 | $6,426 |
| Boston Scientific | 2 | $161 |
| Argenx US, Inc. | 1 | $104 |
| Acorda Therapeutics, Inc | 3 | $60 |
| Biogen | 3 | $53 |
| AstraZeneca | 2 | $32 |
| MDD US Operations, LLC | 1 | $21 |
| Abbott | 1 | $14 |
| Merz North America, Inc. | 1 | $14 |
| Akcea Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA$6,250
- GENERAL DBS$135
- VYVGART$104
How this compares
$62,311 in reported general payments places this provider in the 75th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 107 | $706,400 |
| IngrezzaValbenazine Tosylate | 47 | $333,354 |
| RytaryCarbidopa/Levodopa | 112 | $165,030 |
| NuplazidPimavanserin Tartrate | 29 | $145,754 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 891 | $35,938 |
| NeuproRotigotine | 15 | $15,846 |
| Dalfampridine ErDalfampridine | 26 | $14,655 |
| Primidone | 256 | $10,942 |
| Entacapone | 60 | $10,939 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 179 | $7,797 |
| Propranolol Hcl | 251 | $6,624 |
| MyrbetriqMirabegron | 12 | $6,307 |
| Rasagiline Mesylate | 33 | $6,052 |
| Modafinil | 26 | $5,307 |
| Gabapentin | 234 | $5,234 |
Paid to pharmacies, not to this prescriber.
Other neurology in Scottsdale
- Nida LaurinScottsdale$2.3M
- Allan BlockScottsdale$1.7M
- Virgilio Gerald EvidenteScottsdale$714K
- Brent GoodmanScottsdale$544K
- Dean WingerchukScottsdale$496K
- Meredith WicklundScottsdale$476K
- Erika Driver-DunckleyScottsdale$403K
- Amaal StarlingScottsdale$344K
- David SapersteinScottsdale$289K
- Maciej MrugalaScottsdale$243K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.